ATCC reporter cell lines offer unparalleled precision and efficiency for basic research and biopharma scientists.
- By integrating bioluminescence reporters into biologically relevant tumor cell lines, ATCC provides robust tools for quantifiable, real-time monitoring of gene expression, cellular processes, and drug efficacy.
- Our highly authenticated tumor cell lines with added characterization facilitate high-throughput screening, in vivo imaging, and pathway analysis, significantly accelerating research timelines and enhancing the reliability of experimental outcomes.
- Versatile tools (various reporter formats; luciferase, GFP, dual GFP and luciferase, and inducible) for many scientific applications: Cancer research, stem cell studies, immuno-oncology therapeutic screening, and cell and gene therapy development.
Explore our reporter-labeled cells
Explore our reporter-labeled cells
Take advantage of quantifiable, real-time monitoring of gene expression, cellular processes, and drug efficacy.
Discover versatile tools for immunology studies and immuno-oncology therapeutic development.
Take advantage of quantifiable, real-time monitoring of gene expression, cellular processes, and drug efficacy.
Dual-labeled reporters
ATCC-authenticated CAR-Target and mouse syngeneic reporter lines are now available as dual reporters (GFP and Luciferase).
EMT and MET reporters
ATCC's fluorescently labeled cell lines for the study of epithelial to mesenchymal transition (EMT) and its reverse (MET).
Luciferase-labeled cells
Explore cell lines for in vitro luminescent assays and in vivo live animal bioluminescent imaging.
Discover versatile tools for immunology studies and immuno-oncology therapeutic development.
CAR-Target reporters
Tumor cell lines available as luciferase reporters with additional characterization for the stable expression of emerging CAR-Target antigens.
Checkpoint inhibitor reporters
Inducible luciferase reporter cell lines for use in checkpoint immunotherapy screening and studying immunological responses in vitro and in vivo.
THP-1 reporters
We provide a collection of THP-1 cells with inducible luciferase expression for different immunological functional studies.
The dual-labeled cell advantage
- Real-time visualization: GFP allows for real-time visualization of cellular processes under a microscope, providing immediate feedback on cellular events without the need for additional reagents.
- Quantitative and qualitative data: Combining GFP and luciferase enables both qualitative (visual) and quantitative (luminescent) data collection. This dual approach can provide a more comprehensive and real-time understanding of cellular processes.
- Normalization of data: GFP can serve as an internal control to normalize luciferase activity, reducing variability and improving the accuracy of assay results.
| Designation | ATCC® No. | Disease | Notes | Function | Expression |
| 4T1-GFP-Luc2 | CRL-2539-GFP-LUC2™ | Mimics human breast cancer; Stage IV | Tested in in vivo tumor study | Mouse syngeneic lines for in vivo studies | Constitutive |
| CT26.WT-GFP-Luc2 | CRL-2638-GFP-LUC2™ | Carcinoma | Tested in in vivo tumor study | Mouse syngeneic lines for in vivo studies | Constitutive |
| Raji-GFP-Luc2 | CCL-86-GFP-LUC2™ | Burkitt’s Lymphoma | CAR-T Target: CD19 | Human lines with endogenous CAR-Target | Constitutive |
| NCI-H929-GFP-Luc2 | CRL-3580-GFP-LUC2™ | Plasmacytoma | CAR-T Target: BCMA | Human lines with endogenous CAR-Target | Constitutive |
